FDA Grants DNX-2401 Fast Track Designation for Recurrent Glioblastoma

Share this content:
FDA Grants DNX-2401 Fast Track Designation for Recurrent Glioblastoma
FDA Grants DNX-2401 Fast Track Designation for Recurrent Glioblastoma

DNAtrix announced that the FDA has granted Fast Track status for DNX-2401, a replication competent adenovirus for patients with recurrent glioblastoma.

In a Phase 1 dose-escalating monotherapy study conducted with DNX-2401 for patients with recurrent malignant glioma, efficacy results have been extremely promising, with evidence of total tumor destruction and long-term survival in several patients. A second Phase 1 trial evaluating DNX-2401 in combination with the drug temozolomide is currently ongoing for patients with recurrent glioblastoma.

RELATED: Brain Cancer Resource Center

DNX-2401 is being developed for the treatment of several cancer indications including patients with recurrent glioblastoma.

For more information visit DNAtrix.com.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs